Mpex Pharmaceutical's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex has advanced its lead aerosol antibiotic product Aeroquin (MP-376) through phase 2 clinical development, and its EPI program into lead optimization.